+44 20 8123 2220
info@marketpublishers.com

Global Ovarian Cancer Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

https://marketpublishers.com/r/GD14D287B29EN.html
Date: October 2017
Pages: 209
Price: US$ 4,400.00 (Single User License)
ID: GD14D287B29EN

Abstracts

Global Ovarian Cancer Treatment Market:

Global ovarian cancer treatment market estimated to be valued US$ XX Mn in 2017 and poised to grow at CAGR of XX% over 2017-2023. Market for ovarian cancer treatment is projected to reach US$ XX Mn by 2023.

Ovarian cancer is a type of cancer, which affects ovaries it causes rapid and abnormal increase of cell growth in ovaries. The exact cause of cancer is still unknown. An epithelial tumour, germ cell tumour and primary peritoneal carcinoma are types of ovarian cancer. Common symptoms include pressure in pelvis or lower back, changes in bowel movements, tiredness or low energy and more frequent urination. In most of the ovarian cancer cases, cancer will not be diagnosed until it has progressed to an advanced stage. Ovarian cancer is one of most common cause of cancer deaths in woman. Thereby need for development of the more effective drugs in treatment of ovarian cancer.

Increase in incidence of ovarian cancer worldwide is driving the ovarian cancer treatment market. According to WHO, an estimated 238,700 woman are diagnosed with ovarian cancer in 2012. The increase in older woman population, rising government funding and raising health care awareness able to grow ovarian cancer treatment market over the forecast period. According to ovarian cancer research fund alliance, the rate of prevalence of ovarian cancer is higher in woman between 55 to 66 years, many of the cancer foundations are funding to educate patients and healthcare professionals

regarding symptoms and treatment options for ovarian cancer which may impact ovarian cancer market revenue growth positively over a forecast period. However, availability of generic drugs, lack of accurate diagnosis of ovarian cancer, and patient expiry of the key patented drugs like gemzar, taxol and paraplatin are expected to hamper the ovarian cancer treatment market.

Ovarian cancer treatment market segmented on the basis of type of cancer, drug class, and stage

Based on type of cancer, ovarian cancer treatment market is segmented into

Epithelial Ovarian Tumor

Ovarian Germ Cell Tumor

Ovarian Stomatal Tumor

Primary Peritoneal Carcinoma

Based on drug class, ovarian cancer treatment market is segmented into

Chemotherapeutic Agents

Targeted Therapy Drugs

Immune System Modulators

Hormones

Based on distribution channel, ovarian cancer treatment market is segmented into

Hospital Pharmacies

Retail Pharmacies

Others

Companies operating in ovarian cancer market investing in developing new drug therapies and finding newer molecular targets to treat ovarian cancer. For instance, Vintafolide an investigational targeted cancer therapeutic currently under development by Endocyte and Merck & Co. and faltetuzumab a monoclonal antibody being investigated for the treatment of ovarian cancer this was developed by Morphotek, Inc. The introduction of new drug therapies like gene therapy, radiation therapy and targeted drug therapy are projected to improve ovarian cancer market revenue growth over forecast period. Global ovarian cancer market currently dominated by generic drugs and development of more effective drugs is challenging for market players. Some of the new drugs like avastin, lynparza and yondelis are approved in recent years to treat cancer and these drugs are slowly capturing market share.

Geographically ovarian cancer treatment market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the ovarian cancer treatment market due to rising number of ageing population. According to American cancer society, in U.S. about 22,440 women will receive a new diagnosis of ovarian cancer and about 14,080 women will die from ovarian cancer in 2017. Europe is largest market as the incidence rates of ovarian cancer is increased in the region.

Some of the players in ovarian cancer treatment market include Eli Lilly and Company (U.S.), Johnson & Johnson Services, Inc. (U.S.), Novogen Limited (Australia), Aeterna Zentaris Inc. (U.S)., GlaxoSmithKline plc (UK), Boehringer Ingelheim GmbH (Germany) and F. Hoffmann-La Roche AG (Switzerland) to name a few.

In December 2016 FDA approved rucaparib for the treatment of woman with advanced ovarian cancer who have received two or more prior chemotherapies and whose tumours have BRCA gene mutation

REPORT OUTLINE:

The report provides granular level information about the market size, regional market share and forecast from 2017-2023

The report covers in-detail insights about the competitor’s overview, key findings and their key strategies

The Report Outlines drivers, restraints, challenges, and trends that are currently faced by the industry

+44 20 8123 2220
info@marketpublishers.com

The report tracks recent innovations, key developments and startup's details that are working in the industry

The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario

+44 20 8123 2220
info@marketpublishers.com

Contents

1. EXECUTIVE SUMMARY

2. GLOBAL OVARIAN CANCER TREATMENT MARKET INTRODUCTION

2.1. Global Ovarian Cancer Treatment Market– Taxonomy
2.2. Global Ovarian Cancer Treatment Market–Definitions
  2.2.1. Drug Class
  2.2.2. Cancer Type

3. GLOBAL OVARIAN CANCER TREATMENT MARKET DYNAMICS

3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Ovarian Cancer Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Ovarian Cancer Treatment Market– Regulations
  3.6.1. U.S
  3.6.2. Europe
  3.6.3. Japan
3.7. Global Ovarian Cancer Treatment Market– Recent Product Launches

4. GLOBAL OVARIAN CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023

4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis

5. GLOBAL OVARIAN CANCER TREATMENT MARKET, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023

5.1. Chemotherapeutic Agents
  5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
  5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
  5.1.3. Market Opportunity Analysis
5.2. Targeted Therapy Drugs

5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Immune System Modulators
5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Hormones
5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis

6. GLOBAL OVARIAN CANCER TREATMENT MARKET FORECAST, BY CANCER TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023

6.1. Epithelial Ovarian Tumor
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Ovarian Germ Cell Tumor
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Ovarian Stomatal Tumor
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis

7. GLOBAL OVARIAN CANCER TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023

7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis

7.3. Others
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis

8. GLOBAL OVARIAN CANCER TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023

8.1. North America
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia-Pacific
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
8.6. Global Ovarian Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Region, 2017 – 2023

9. NORTH AMERICA OVARIAN CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

9.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
9.1.1.1. Chemotherapeutic Agents
9.1.1.2. Targeted Therapy Drugs
9.1.1.3. Immune System Modulators

9.1.1.4. Hormones
9.1.2. Cancer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.2.1. Epithelial Ovarian Tumor
9.1.2.2. Ovarian Germ Cell Tumor
9.1.2.3. Ovarian Stomatal Tumor
9.1.2.4. Primary Peritoneal Carcinoma
9.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
9.1.3.1. Hospital Pharmacies
9.1.3.2. Retail Pharmacies
9.1.3.3. Others
9.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
9.1.4.1. U.S.
9.1.4.2. Canada
9.1.5. North America Ovarian Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2017 – 2023
9.1.6. North America Ovarian Cancer Treatment Market Dynamics – Trends

10. EUROPE OVARIAN CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

10.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
10.1.1.1. Chemotherapeutic Agents
10.1.1.2. Targeted Therapy Drugs
10.1.1.3. Immune System Modulators
10.1.1.4. Hormones
10.1.2. Cancer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.2.1. Epithelial Ovarian Tumor
10.1.2.2. Ovarian Germ Cell Tumor
10.1.2.3. Ovarian Stomatal Tumor
10.1.2.4. Primary Peritoneal Carcinoma
10.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.3.1. Hospital Pharmacies
10.1.3.2. Retail Pharmacies

10.1.3.3. Others
10.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.4.1. Germany
10.1.4.2. UK
10.1.4.3. France
10.1.4.4. Spain
10.1.4.5. Italy
10.1.4.6. Russia
10.1.4.7. Poland
10.1.4.8. Rest of Europe
10.1.5. Europe Ovarian Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2017 – 2023
10.1.6. Europe Ovarian Cancer Treatment Market Dynamics – Trends

11. ASIA-PACIFIC OVARIAN CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

11.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
11.1.1.1. Chemotherapeutic Agents
11.1.1.2. Targeted Therapy Drugs
11.1.1.3. Immune System Modulators
11.1.1.4. Hormones
11.1.2. Cancer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.2.1. Epithelial Ovarian Tumor
11.1.2.2. Ovarian Germ Cell Tumor
11.1.2.3. Ovarian Stomatal Tumor
11.1.2.4. Primary Peritoneal Carcinoma
11.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.3.1. Hospital Pharmacies
11.1.3.2. Retail Pharmacies
11.1.3.3. Others
11.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
11.1.4.1. Japan

11.1.4.2. China
11.1.4.3. India
11.1.4.4. ASEAN
11.1.4.5. Australia & New Zealand
11.1.4.6. Rest of Asia-Pacific
11.1.5. Asia-Pacific Ovarian Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2017 – 2023
11.1.6. Asia-Pacific Ovarian Cancer Treatment Market Dynamics – Trends

12. LATIN AMERICA OVARIAN CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

12.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
12.1.1.1. Chemotherapeutic Agents
12.1.1.2. Targeted Therapy Drugs
12.1.1.3. Immune System Modulators
12.1.1.4. Hormones
12.1.2. Cancer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.2.1. Epithelial Ovarian Tumor
12.1.2.2. Ovarian Germ Cell Tumor
12.1.2.3. Ovarian Stomatal Tumor
12.1.2.4. Primary Peritoneal Carcinoma
12.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.3.1. Hospital Pharmacies
12.1.3.2. Retail Pharmacies
12.1.3.3. Others
12.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.4.1. Brazil
12.1.4.2. Mexico
12.1.4.3. Argentina
12.1.4.4. Venezuela
12.1.4.5. Rest of Latin America
12.1.5. Latin America Ovarian Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2017 – 2023
12.1.6. Latin America Ovarian Cancer Treatment Market Dynamics – Trends

13. MIDDLE EAST & AFRICA OVARIAN CANCER TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023

13.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.1.1. Chemotherapeutic Agents
13.1.1.2. Targeted Therapy Drugs
13.1.1.3. Immune System Modulators
13.1.1.4. Hormones
13.1.2. Cancer Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.2.1. Epithelial Ovarian Tumor
13.1.2.2. Ovarian Germ Cell Tumor
13.1.2.3. Ovarian Stomatal Tumor
13.1.2.4. Primary Peritoneal Carcinoma
13.1.3. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.3.1. Hospital Pharmacies
13.1.3.2. Retail Pharmacies
13.1.3.3. Others
13.1.4. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
13.1.4.1. Gulf Cooperation Council (GCC) Countries
13.1.4.2. Israel
13.1.4.3. South Africa
13.1.4.4. Rest of MEA
13.1.5. MEA Ovarian Cancer Treatment Market- Opportunity Analysis Index - By Drug Class, By Cancer Type, By Distribution Channel, and Country, 2017 – 2023
13.1.6. MEA Ovarian Cancer Treatment Market Dynamics – Trends

14. COMPETITION LANDSCAPE

14.1. Strategic Dashboard of Top Market Players
14.2. Company Profiles (Introduction, Financial Analysis, Product & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
14.2.1. Eli Lilly and Company (U.S.)
14.2.2. Johnson & Johnson Services, Inc. (U.S.)
14.2.3. Novogen Limited (Australia)

+44 20 8123 2220
info@marketpublishers.com

14.2.4. Aeterna Zentaris Inc. (U.S)
14.2.5. GlaxoSmithKline plc (UK)
14.2.6. Boehringer Ingelheim GmbH (Germany
14.2.7. F. Hoffmann-La Roche AG (Switzerland)

15. RESEARCH METHODOLOGY

16. KEY ASSUMPTIONS AND ACRONYMS

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Global Ovarian Cancer Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023

Product link: https://marketpublishers.com/r/GD14D287B29EN.html

Price: US$ 4,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GD14D287B29EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

+44 20 8123 2220
info@marketpublishers.com